United States· US:0006-0081_4323fb1c-54a7-4648-bfe0-28fb4cb65f50
JANUMET
A metformin and sitagliptin product containing sitagliptin phosphate; metformin hydrochloride, registered in United States by Merck Sharp & Dohme LLC. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Metformin and sitagliptin is registered in 14 of 19 countries.
Countries holding a registration under ATC A10BD07 (metformin and sitagliptin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Metformin and sitagliptin · ATC A10BD07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE
- Manufacturer
- Merck Sharp & Dohme LLC
- Country
- United States (US)
- ATC code
- A10BD07
- ATC class
- Metformin and sitagliptin
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 23, 2026
Packs & prices · 8
- ndc1100060081142 BOTTLE in 1 CARTON (0006-0081-14) / 7 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0006-0081-07)
- ndc11000600813130 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0006-0081-31)
- ndc11000600815490 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0006-0081-54)
- ndc1100060081821000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0006-0081-82)
- ndc110006-0081-14
- ndc110006-0081-31
- ndc110006-0081-54
- ndc110006-0081-82
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for metformin and sitagliptin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and sitagliptin · interactions on record
3 records
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f48ab1d1-e784-41ff-a6b4-4c2d680229d3 GET /v1/drugs/f48ab1d1-e784-41ff-a6b4-4c2d680229d3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "1000; 100",
"substance": "SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE",
"productndc": "0006-0081",
"dosage_form": "TABLET, FILM COATED, EXTENDED RELEASE",
"dea_schedule": null,
"strength_unit": "mg/1; mg/1",
"application_number": "NDA202270",
"marketing_category": "NDA"
}See everything about metformin and sitagliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.